3020 Results
Sort By:
Published on January 19, 2024
In a crucial Phase I/II trial, researchers at The University of Texas MD Anderson Cancer Center have reported significant success in treating patients with relapsed or refractory B-cell malignancies using cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. The findings, published in Nature Medicine, show…
Published on January 3, 2024
In what could be a big step forward for immunotherapy, ”unprecedented NK [natural killer] cell-engaging Nanodrones” that can selectively target specific cancer cells have been developed, by researchers at Ulsan National Institute of Science and Technology (UNIST). This approach, the researchers suggest, could be used to address types of cancers…
Published on February 22, 2023
The University of Texas MD Anderson Cancer Center and Replay have launched Syena, an oncology-focused company developing novel T cell receptor (TCR) natural killer (NK) cell therapies. The new company’s TCR NK cell platform is based upon the scientific discoveries of Katy Rezvani, MD, PhD, professor of Stem Cell Transplantation &…
Published on October 20, 2022
Xcell Biosciences and aCGT Vector have announced a collaboration for manufacturing and analysis around personalized cell and gene therapies for cancer patients. aCGT Vector will provide its point-of-care GMP-licensed manufacturing platform to validate Xcellbio’s manufacturing and analytical AVATAR AI technology for use in precision cancer treatment. The partnership pairs aCGT’s…
Published on October 5, 2022
A team of researchers at the University of Texas MD Anderson Cancer Center say they have developed a novel approach to the engineering of natural killer (NK) cells that improves tumor specificity and anti-tumor activity. The newly developed cells overcome NK cell dysfunction and tumor relapse via the addition of…
Published on April 14, 2022
A kind of kiss between cells, called trogocytosis, which can shut down anticancer activity plays a key role in the battle between the immune system and blood cancer cells, suggests early stage research from the University of Ottawa. “Trogocytosis modulates immune responses, with still unclear underlying molecular mechanisms,” the researchers…
Published on December 14, 2022
Researchers from the University of Pennsylvania have discovered that a small molecule KRAS-targeted therapy stopped cancer growth or shrank tumors in animal models of pancreatic cancer. They found that the drug inhibits the activity of the most common KRAS mutation in pancreatic cancer and simultaneously boosts T cells mediated immunity.…
Published on December 7, 2022
Cancer patients’ response to immunotherapy may be predictable in part based on their levels of CD8+ T-cell infiltration, according to a new study. Such drugs are one of the world’s highest selling classes, estimated to have netted over $31B in 2021 and expected to bring almost $150M by 2030. But…
Published on August 4, 2022
Women with a history of severe preeclampsia have more markers linked to brain cell damage, inflammation, and possibly Alzheimer’s, Mayo Clinic researchers say. Their findings were presented this week at the Alzheimer’s Association International Conference in San Diego. Preeclampsia is a serious complication of pregnancy characterized by high blood pressure and kidney damage.…
Published on June 6, 2022
With eyes on the future of the coming wave of approved, personalized cell therapies for a range of diseases, life sciences company GoodCell announced it is launching its Personal Biobanking Service that allows individuals to proactively collect and store their stems cells that can be used in the future for…
Published on May 24, 2022
Crown-like structures (CLSs) associated with the fat cells in HER2+ breast tumors could hinder the response of some patients to therapy, according to research from the University of Southampton. The results showed that CLSs were more commonly found at the adipose-tumor border (B-CLS) in HER2+ breast cancer, and also linked…
Published on April 21, 2022
Extra copies of a piece of DNA help explain insensitivity to chemotherapy in germ cell cancer, a new study shows. In cell line models of germ cell tumors (GCTs) copy number gain of chromosome 3 cytoband p25.3 was associated with cisplatin resistance. While cisplatin is generally effective in GCTs, 5%…
Published on March 29, 2022
Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital have profiled, at single-cell resolution, the genes expressed in each trigeminal ganglion (TG) cell type. Their atlas may lead to the development of more effective treatments for migraine. Migraine and related headaches are caused by activity in the TG part…
Published on January 28, 2022
Researchers at the University of California, San Francisco (UCSF), and colleagues have categorized all the cells that form the blood vessels of the human brain, along with their locations and the genes transcribed in each. The atlas characterizes more than 40 previously unknown cell types. The team suggests that their…
Published on August 25, 2021
Researchers at the Japanese Foundation for Cancer Research (JFCR), have discovered that noncoding RNA (ncRNA) derived from pericentromeric repetitive elements can provoke inflammatory gene expression during senescence and cancer. Ordinarily, in young cells, these elements are silenced by the CCCTC-binding factor (CTCF). However, in senescent cells, ncRNA derived from these…